October 2024

Drug patent abandonment is not a clerical failure. It is a calculated move within a broader lifecycle management strategy or […]

In the high-stakes world of pharmaceutical development, the race to bring life-changing therapies to patients is more complex and competitive

Part I: Anatomy of a Crisis – The Landscape of Generic Drug Shortages Section 1: The Paradox of the Modern

The modern generic drug industry is a paradox. On one hand, it stands as one of the most successful public

In the high-stakes world of pharmaceutical intellectual property, where a single patent can shield billions in revenue and a decade

The global pharmaceutical industry stands at a pivotal juncture. While established markets continue to offer stability, the undeniable trajectory of

Part 1: The Bedrock of Biosimilarity: Foundational Principles Beyond “Generic Biologics”: A New Paradigm for Competition and Access In the

In the intricate and often contentious world of American healthcare, a powerful and unsustainable collision is underway. On one side,

Executive Summary The advent of biosimilars represents the most significant structural shift in the biopharmaceutical landscape since the Hatch-Waxman Act